That said, I think this is an interesting approval, but I do not expect it to dramatically reshape the GLP-1 landscape, he went on
The findings from the FLOW trial have the potential to change the disease course of these high-risk patients and pave the way for new treatment strategies, offering hope to millions of patients globally. Pratley et al note that new research will follow in 2024 and 2025, which will be looking into clinically relevant areas to address the unmet needs of this patient population.
Compounded GLP-1 medications carry the same clinical benefits and risks as branded versions, though sourcing from licensed 503A pharmacies ensures pharmacy-level quality oversight
The same mental health issues we see with bariatric surgery, were going to see in psychological weight agents
Before we explore the lesser-known effects, let's review the commonly reported ones
your relationship with it simply changes